Evotec SE has achieved key progress in its long-standing neuroscience collaboration with Bristol Myers Squibb, triggering a $20 million research payment to Evotec, enabling further development of a preclinical program in neurodegeneration. The strategic collaboration began in December 2016 and the companies have been working to identify disease-modifying treatments for a broad range of neurodegenerative diseases. While currently approved therapies primarily focus on symptom management, this p...